Nasty US flu season gives Clorox big profits
Sales of disinfectant wipes and bleach are on the rise while Americans battle norovirus and other germs.
Clorox (CLX) sales were up 9% to $1.33 billion last quarter, thanks to a particularly nasty flu season that's increased demand for its disinfecting wipes and the concentrated version of its namesake bleach. Those gains should trickle through the rest of the year, too, as Clorox increased its outlook from an increase between 2% and 4% to a bigger boost somewhere between 3% and 5%.
Sales of Clorox cleaning products alone jumped 15% to $425 million and increased income 28%. Household sales surged 7% and profits rose 65% as both prices and demand increased and a germ-averse public stocked up.
Between strains of flu not covered by this year's flu shot and an absolutely grotesque norovirus import from Australia that's been putting gastrointestinal systems to the test, it's been a tough few weeks fraught with peril and hand washing for the average American.
Germ-slicked menus and wait staff who aren't given sick days have made restaurants dicey propositions for folks who've seen "Contagion" one too many times. Meanwhile, the Centers for Disease Control and Prevention estimates that this year's flu outbreak will cost employers upwards of $10 billion for treatment and hospitalization while medical centers are seeing their supplies dwindle to nearly nil.
However, it's not just America's unfortunate bout of illness that has Clorox's numbers looking so well. Sales of its Burt's Bees organic skin care products and Brita water filters helped increase sales within its lifestyle segment by 8%. Also, price hikes around the globe helped increase revenue 3%.
All together, Clorox earned $123 million, or 93 cents per share, in its second quarter. That's not shabby when compared with a profit of $105 million, or 79 cents per share, a year earlier. Even with U.S. flu season winding down, those multilayered numbers may stay healthy until the worst is over.
More on moneyNOW
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
Strong sales in November kept a strong year on course, and solid profit margins helped as well.
- Can you opt out of Medicare?
- Student loan debt climbs for 5th year in a row
- Plans revived for 'floating city' of 50,000 people
- Homeowners insurance: Bountiful coverage for bad cooking
- 3 stocks for the 3-D printing revolution
- Why restaurants are adding tablets to the tables
- America's greatest export is its debt
- True test for Obamacare: Will it make US healthier?
- Who will foot the bill for Detroit's bankruptcy?
[BRIEFING.COM] Precious metals are weak this morning on growing speculation of a Fed taper following strong economic data released earlier today. The GDP was revised up to 3.6% in the second estimate of 3Q2013 GDP from 2.8% in the advance release. That is up from a 2.5% gain in the second quarter and the largest increase since growing 3.9% in 2Q2010. Feb gold pulled back from its session high of $1229.70 and is now trading 2.4% lower at $1217.20. Mar silver dipped to a session low of $19.22 ... More
More Market News
The Street's 'corrective action' made an attractive company that is growing profitability even more appetizing.